CEL-SCI Corporation (CVM)
NYSEAMERICAN: CVM · Real-Time Price · USD
0.394
-0.002 (-0.43%)
Feb 24, 2025, 3:11 PM EST - Market open
CEL-SCI Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
43
Market Cap
30.44M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
CVM News
- 4 days ago - CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial - Business Wire
- 6 days ago - CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks - Business Wire
- 5 weeks ago - CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer - Business Wire
- 7 weeks ago - CEL-SCI Announces Closing of $5 Million Offering - Business Wire
- 2 months ago - CEL-SCI Announces Pricing of $5 Million Public Offering - Business Wire
- 2 months ago - CEL-SCI Announces Proposed Public Offering of Common Stock - Business Wire
- 2 months ago - CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study - Business Wire
- 3 months ago - Stock Picks From Seeking Alpha's October 2024 New Analysts - Seeking Alpha